Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMC435 in Treatment-Naive Genotype 1 Hepatitis C in Japan
NCT01292239Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2011
- Primary completion
- Oct 2012
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatitis C (HCV) comparing TMC435 + PR with Placebo + PR (2 arms). Primary endpoint: Sustained Virologic Response at 12 Weeks After Last Dose. Started Feb 2011; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01292239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292239.